Enzalutamide

Xtandi

Androgen Receptor Inhibitor

NADAC/unit N/A

No Shortage Tier 1: 53.8% PA Req: 298.2%

XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensiti....

Covered Lives

Generic Manufacturers

ASTELLAS PHARMA US INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Enzalutamide drfinder.aiFind doctors who prescribe Enzalutamide rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Enzalutamide

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.